GEIS is an internationally renowned non-profit organization focused on the research and development of drugs for sarcoma cancers.

GEIS will be conducting a multi-country, randomized, open-label Phase 2 clinical trial in a first line setting to evaluate camsirubicin head-to-head against doxorubicin in patients with advanced soft tissue sarcoma.